What is hepatorenal syndrome?

What is Hepatorenal Syndrome?

Hepatorenal syndrome (HRS) is a specific form of functional kidney failure that occurs in patients with advanced cirrhosis and ascites, characterized by renal vasoconstriction and reduced glomerular filtration rate in the absence of intrinsic kidney disease. 1, 2

Pathophysiology

HRS develops from a complex interplay of hemodynamic disturbances and systemic inflammation 2, 3:

• Splanchnic vasodilation from portal hypertension leads to reduced effective arterial blood volume
• This triggers compensatory activation of vasoconstrictor systems (renin-angiotensin-aldosterone, sympathetic nervous system)
• Extreme renal vasoconstriction results, causing decreased kidney perfusion and GFR
• Systemic inflammation and bacterial translocation play increasingly recognized roles in precipitating HRS 2, 3

The kidneys themselves have no structural damage—this is purely functional renal failure that can reverse with appropriate treatment.

Updated Classification

The traditional HRS-1 and HRS-2 terminology has been revised 1, 4:

HRS-AKI (formerly Type 1 HRS)

• Rapid, progressive kidney dysfunction
• Defined by increase in serum creatinine ≥0.3 mg/dL within 48 hours OR ≥50% from baseline
• No longer requires reaching a threshold of 1.5 mg/dL, allowing earlier treatment initiation 1
• Often triggered by infection, gastrointestinal bleeding, or large-volume paracentesis
• Carries very high short-term mortality without treatment

HRS-NAKI/HRS-CKD (formerly Type 2 HRS)

• Slower, progressive course
• Associated with refractory ascites
• Does not meet criteria for acute kidney injury

Diagnostic Criteria

HRS is a diagnosis of exclusion requiring 5:

1. Cirrhosis with ascites
2. Serum creatinine ≥1.5 mg/dL (or meeting AKI criteria for HRS-AKI)
3. No improvement after at least 2 days of diuretic withdrawal AND volume expansion with albumin (1 g/kg/day up to 100 g/day)
4. Absence of shock
5. No current or recent nephrotoxic drugs
6. Absence of parenchymal kidney disease:
   • Proteinuria <500 mg/day
   • No microhematuria (>50 RBCs per high-power field)
   • Normal renal ultrasonography

Critical Diagnostic Pitfall

Differentiating HRS-AKI from acute tubular necrosis (ATN) is challenging but essential 2, 3. These conditions may exist on a continuum rather than as distinct entities. Emerging biomarkers may help, but clinical judgment remains paramount—vasoconstrictors are not indicated for ATN.

Clinical Significance

• HRS-AKI has dismal prognosis without treatment: historically near 100% mortality without liver transplantation 5, 6
• Even with successful medical treatment, recurrence is common and long-term survival poor without transplantation 7
• Patients with HRS have lower survival after liver transplantation compared to those without HRS, though transplantation remains their only definitive cure 7
• Quality of life is severely impaired in patients with HRS 2

Management Principles

The cornerstone of HRS-AKI treatment involves 7, 1, 4:

First-Line Pharmacologic Therapy

Vasoconstrictors plus albumin:

• Terlipressin (1 mg IV every 4-6 hours) with albumin is first-line where available 7
• If no 25% creatinine decrease after 3 days, increase stepwise to maximum 2 mg every 4 hours
• Discontinue after 14 days if no response
• Norepinephrine is second-line (requires ICU setting) 4
• Midodrine/octreotide combination has lower efficacy but can be given outside ICU 5, 4

Definitive Treatment

Liver transplantation is the only curative treatment for both HRS-AKI and HRS-CKD 7:

• Survival approximately 65% in HRS-AKI patients post-transplant 7
• Patients should receive expedited transplant listing given high waitlist mortality 7
• Combined liver-kidney transplantation may be needed only if prolonged renal support >12 weeks 7

Adjunctive Measures

• Renal replacement therapy for non-responders who are transplant candidates 7
• TIPS has insufficient data to recommend routinely for HRS-AKI 7

Key Clinical Pearls

• HRS represents the extreme end of circulatory dysfunction in cirrhosis—the kidneys are "innocent bystanders"
• Early recognition is critical: the updated definition allowing treatment before creatinine reaches 1.5 mg/dL improves outcomes 1
• All patients with HRS-AKI should be urgently evaluated for liver transplantation 4
• Even responders to medical therapy have poor prognosis without transplantation 7
• Multidisciplinary management involving hepatology, nephrology, and transplant surgery is essential 4, 8